Recent FDA Approved Drug

Uplizna (Inebilizumab) for the treatment of (Neuro Myelitis Optica Spectrum Disorder) 

The USFDA has approved Inebilizumab

for the treatment of NMOSD who are anti- AQP-4 Antibody positive

About AQP-4 : 

It is a water channel Aquaporin -4 antibody is one of the family of membrane water transport proteins some of which transport glycerol & other small solutes. There are atleast 12 AQP proteins expressed in mammalian tissues.

AQP-4 is a target for NMO autoimmune Antibody.

About NMOSD: It is a rare, severe neuroinflammatory autoimmune disorder that attacks the Optical nerve,spinal cord and brain stem .These cause irreversible blindness & paralysis also.